Carboxyl-Terminal Repressor Domain of MBP-1 is Sufficient for Regression of Prostate Tumor Growth in Nude Mice

Asish K. Ghosh, Robert Steele, and Ratna B. Ray

Abstract

Prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of male cancer death in the United States. Early detection and improved procedures for surgical intervention and radiation therapy have reduced the fatalities; however, there is no effective cure for men with advanced disease and additional therapy is urgently needed. We have previously shown that MBP-1 acts as a general transcriptional repressor and exerts an antiproliferative effect on several human cancer cells. MBP-1 possesses two repressor domains, located at the amino and carboxyl termini. In this study, we have examined the potential of the repressor domains of MBP-1 as a gene therapeutic candidate in regression of prostate tumor growth. Our results suggested that replication-deficient adenovirus-mediated delivery of amino-terminal (MBP-AR) or carboxyl-terminal (MBP-CR) repressor domain of MBP-1 exerted an antiproliferative effect, like the full-length MBP-1, and induced caspase-independent apoptosis in prostate cancer cells. Next, we investigated the therapeutic effectiveness of MBP-1 repressor domain on prostate tumors. When tested in human tumor xenografts in nude mice, MBP-CR suppressed prostate tumor growth more effectively than full-length MBP-1, whereas MBP-AR delayed prostate tumor growth. Together, these results suggested that MBP-CR expression has an antiproliferative effect in human prostate cancer cells, being more effective than the full-length MBP-1 in preventing tumor growth. (Cancer Res 2005; 65(3): 718-21)

Introduction

Prostate cancer is the second leading cause of cancer death among males in the United States. Although survival rates are good for prostate cancer on early diagnosis, and many patients in this group can be cured by radical prostatectomy or radiation therapy, a significant number will develop local recurrence within the prostate, and some ultimately will develop disseminated disease (1). In 2003, an estimated 220,900 American men were diagnosed with prostate cancer, and ~28,900 men died from the disease (2). Therefore, more effective therapies that can cure localized tumors and prevent their metastasis are urgently needed. Considerable interest has been shown in the discovery of cellular genes, which seem to be antiproliferative in gene therapy studies (3). We have identified a novel cellular gene MBP-1 from a human cervical carcinoma cell expression library (4). MBP-1, an ~37 kDa cellular protein, has multiple functions. MBP-1 binds to the c-myc promoter sequences and transcriptionally represses the c-myc gene (4-7). Subsequent studies suggested that MBP-1 acts as a general transcriptional repressor (8). Structure/function analysis of MBP-1 mutants revealed that the transcriptional repressor domains are located in the amino-terminal (MBP-AR) and carboxyl-terminal (MBP-CR) regions. Ectopic expression of MBP-1 induces cell death in murine fibroblasts (6) and regresses human breast tumor growth in nude mice (9). In this study, we have examined the potential of MBP-1 repressor domain as a gene therapeutic candidate in regression of prostate tumor growth.

Materials and Methods

Cell Lines. Androgen-independent prostate cancer cell lines, DU145 and PC3, were purchased from American Type Culture Collection and maintained in DMEM containing 10% fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin in a humidified CO2 incubator.

Generation of MBP-AR or MBP-CR in Replication-Deficient Recombinant Adenovirus. The cDNA encoding the amino acid residues 1 to 95 (MBP-AR) or the amino acid residues 190 to 338 (MBP-CR) fused to Flag-epitope were cloned into replication-deficient adenovirus as described previously (10). The expression of MBP-AR or MBP-CR in the recombinant adenovirus was verified by Western blot analysis using an antibody to Flag.

Full-length MBP-1 expressing recombinant adenovirus (AdMBP-1) and Ad5-gal were also used in this study (11). All recombinant adenovirus constructs were purified using CsCl density gradient (11).

Cell Proliferation Assay. PC3 cells were infected with Ad5-gal (control virus), AdMBP-1, AdMBP-AR, or AdMBP-CR. Cell viability was determined by trypan blue exclusion at 0, 48, 72, and 120 hours following transduction.

DNA Fragmentation. PC3 cells were infected with the Ad5-gal, AdMBP-1, AdMBP-AR, or AdMBP-CR at 100 multiplicity of infection. After 72 hours of infection, cells were treated with lysis buffer [10 mmol Tris (pH 8.0), 1 mmol EDTA, 100 mmol NaCl, 1.0% SDS, and 200 μg/mL proteinase K]. Genomic DNA was isolated and analyzed on a 1.4% agarose gel by electrophoresis as described previously (6).

PARP Cleavage and Activation of Caspases. PC3 cells were transduced with Ad5-gal, AdMBP-1, AdMBP-AR, or AdMBP-CR for 72 hours. Cell lysates were subjected to Western blot analysis using a rabbit polyclonal antibody to PARP (Alexis, San Diego, CA) or antibodies to procaspase-9 and procaspase-3 (PharMingen, San Diego, CA).

Tumorigenicity Assay. Male BALB/c athymic nude mice (5-7 weeks old) were purchased from Harlan Sprague-Dawley (Indianapolis, IN). In the first set of experiments, prostate cancer cells were transduced with Ad5-gal, AdMBP-1, AdMBP-AR, or AdMBP-CR. After 48 hours of infection, cells were trypsinized, washed and the cell suspension was injected s.c. in the flank region of nude mice. Tumor growth was monitored weekly using a slide caliper. In the second set of experiments, prostate cancer cells were harvested, washed with PBS and resuspended in DMEM containing 40% matrigel (BD Biosciences, Bedford, MA). Male nude mice were injected s.c. into each posterior flank region with 4.0 × 10³ cells (0.1 mL amount). Tumors were allowed to grow and gene transfer treatment was started when they reached a mean volume of 88 mm³. A dose of ~5 × 10⁵ virus particles of Ad5-gal, AdMBP-1 or AdMBP-CR was given intratumorally (i.t.) every 48 hours for a total of three injections. Another group of mice received saline and were used as controls. Regression of tumor growth was monitored weekly using a slide caliper and their volume was calculated by employing the following formula: [length × (width)²] / 2. All mice were sacrificed when tumor growth reached ~1,500 mm³ using the highest
results and discussion

generation of recombinant adenovirus expressing repressor domains of MBP-1. We have shown previously that MBP-1 possesses two independent, separable transcriptional repressor domains located at the NH2- and COOH-terminals (8). To investigate whether the repressor domains of MBP-1 exert antiproliferative activity, we generated recombinant adenovirus (Fig. 1A) expressing the amino-terminal repressor domain (AdMBP-AR) or carboxy-terminal repressor domain (AdMBP-CR). To examine the expression of AdMBP-AR or AdMBP-CR, PC3 cells were infected and cell lysates were prepared after 72 hours of infection and analyzed by Western blot using an antibody to Flag. Results showed expression of both the deletion mutants of MBP-1 in PC3 cells on transduction of AdMBP-AR and AdMBP-CR (data not shown).

antiproliferative effect of MBP-AR or MBP-CR on prostate cancer cells. To examine whether expression of MBP-AR or MBP-CR has an effect on prostate cancer cell growth, PC3 cells were transduced with either Adβ-gal, AdMBP-AR, or AdMBP-CR. Cell viability was determined by trypan blue exclusion at various time periods (0, 48, 72, and 120 hours). AdMBP-1 was used in parallel for comparison. Our results showed a significant reduction in cell viability between 48 and 72 hours following transduction with AdMBP-AR or AdMBP-CR when compared with that of Adβ-gal (Fig. 1B). Similar results were obtained when DU145 cells were transduced with these recombinant adenoviruses. These results suggested that both MBP-AR and MBP-CR exert antiproliferative effects, like full-length MBP-1, on prostate cancer cell growth in vitro.

MBP-AR or MBP-CR induces apoptosis in prostate cancer cells. We next determined whether the MBP-AR or MBP-CR-mediated inhibition of prostate cancer cell growth is due to induction of apoptosis. For this, we examined intranucleosomal DNA fragmentation in cells infected with either Adβ-gal, AdMBP-AR, or AdMBP-CR. AdMBP-1 was used in parallel for comparison. DNA was isolated from cells after 72 hours of infection and analyzed by agarose gel electrophoresis. We observed the intranucleosomal DNA fragmentation in cells transduced with full-length MBP-1, MBP-AR, or MBP-CR (Fig. 2A). However, cells transduced with Adβ-gal did not exhibit detectable DNA fragmentation. Thus, both the repressor domains of MBP-1 induce apoptosis in prostate cancer cells.

To further investigate the effect of MBP-1 repressor domain on the apoptotic signaling pathway, PARP cleavage was examined in the lysates of prostate cancer cells (PC3) transduced with recombinant adenoviruses for 72 hours by Western blot analysis using a specific antibody (Fig. 2B). Cells transduced with AdMBP-AR or AdMBP-CR, as well as AdMBP-1, displayed a cleavage of ~116 kDa native PARP to its ~86 kDa signature polypeptide. Cells transduced with Adβ-gal for 72 hours or left untreated did not display any detectable amount of ~86 kDa PARP cleavage product. Therefore, these results suggested that MBP-1-mediated apoptosis involves PARP cleavage. We further analyzed the activation of procaspase-9 and procaspase-3 from AdMBP-1-transduced cells by Western blot using specific antibodies, and did not observe activation. Treatment of cells with a pan-caspase inhibitor, zVAD-fmk, could not protect from MBP-1-induced apoptosis or PARP cleavage (Fig. 2B, lane 6), suggesting that MBP-1-induced apoptosis in PC3 cells may occur independent of caspase activation. Translocation of apoptosis-inducing factor from mitochondria into the nucleus also induces apoptosis without activation of caspases (12). Here, we did not observe translocation of apoptosis-inducing factor from mitochondria into the nucleus of prostate cancer cells expressing MBP-1 or its repressor domain (data not shown), suggesting that MBP-1-mediated apoptosis does not involve this pathway. Our results also suggested that apoptosis in PC3 cells mediated by MBP-1 repressor domains follow different pathways as compared with HeLa or MCF-7 cells (11). Further in-depth mechanism of MBP-1-mediated apoptosis in prostate cancer (PC3) cells remains to be elucidated.

effect of MBP-AR and MBP-CR on prostate tumor growth in vivo. To investigate whether MBP-AR or MBP-CR could regress prostate tumor growth, DU145 and PC3 cells were transduced with Adβ-gal, AdMBP-AR, and AdMBP-CR, or left untreated. Full-length MBP-1 (AdMBP-1) was used in parallel for comparison. After 48 hours of infection, cells were harvested, washed and injected s.c. into the flanks of nude mice. None of the athymic nude mice given an injection of MBP-CR or full-length MBP-1-transduced cells
showed tumor formation during the observation period (Table 1). However, Ad\(_{\beta-}\)gal-transduced control cells and uninfected cells implanted in nude mice displayed tumor growth and were sacrificed at day 19 (DU145) or day 44 (PC3) after injection for large tumor burden. Expression of MBP-AR delayed tumor growth and then continued to grow until the mice were sacrificed. These results suggested that the MBP-CR and full-length MBP-1 are able to inhibit in vivo prostate tumor growth.

Next, we examined whether the MBP-CR or full-length MBP-1 has a therapeutic effect in regression of prostate tumor growth. For this, 4\( \times \)10\^6 cells mixed with 40% matrigel were injected at each site in the flank region of male nude mice. When the tumor volume reached an average volume of 88 mm\(^3\), the mice were randomized into different treatment groups for administration of recombinant adenovirus constructs. A dose of 5 \( \times \) 10\(^9\) virus particles of Ad\(_{\beta-}\)gal, AdMBP-CR, or AdMBP-1 was given i.t. every 48 hours for a total of three injections. Another group of mice bearing prostate tumors were injected with saline at the same interval and used as control.

### Table 1. Antitumor effect of MBP-CR in prostate cancer cells implanted in athymic nude mice

<table>
<thead>
<tr>
<th>Xenograft model</th>
<th>Treatment group</th>
<th>Tumorigenicity</th>
<th>Latency (d)</th>
<th>Day of sacrifice *</th>
</tr>
</thead>
<tbody>
<tr>
<td>DU145</td>
<td>Uninfected</td>
<td>4/4</td>
<td>7</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Ad(_{\beta-})gal</td>
<td>4/4</td>
<td>7</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>AdMBP-1</td>
<td>0/4</td>
<td>NA (^1)</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>AdMBP-AR</td>
<td>3/4</td>
<td>26</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>AdMBP-CR</td>
<td>0/4</td>
<td>NA (^1)</td>
<td>43</td>
</tr>
<tr>
<td>PC3</td>
<td>Uninfected</td>
<td>4/4</td>
<td>19</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>Ad(_{\beta-})gal</td>
<td>3/4</td>
<td>19</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>AdMBP-1</td>
<td>0/4</td>
<td>NA (^1)</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>AdMBP-AR</td>
<td>2/4</td>
<td>29</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>AdMBP-CR</td>
<td>0/4</td>
<td>NA (^1)</td>
<td>55</td>
</tr>
</tbody>
</table>

* Mice were sacrificed because of large tumor burden.

\(^1\) NA, not applicable.

Figure 3. Evaluation of AdMBP-CR and AdMBP-1-mediated gene transfer in human prostate tumor xenografts. PC3 cells were implanted s.c. into the flanks of male nude mice. Tumor bearing mice were randomized into different treatment groups for i.t. administration of saline, Ad\(_{\beta-}\)gal, AdMBP-1, or AdMBP-CR, when the tumor size reached an average volume of 88 mm\(^3\). A total of three i.t. injections were applied for each construct at every 48-hour interval. Points, mean volume of tumor growth monitored weekly; bars, SE; arrowheads, day of injections; *, significant difference (\(P < 0.001\)) from the control groups; **, significant difference (\(P < 0.0001\)) from the control groups.
Because we observed the delayed tumor growth from AdMBP-AR-infected prostate cancer cells, we did not include AdMBP-AR in this part of our study. The tumor volume from the control groups (treated with saline or Ad[β-gal]) steadily increased with time and mice were sacrificed at day 57 because of tumor burden (Fig. 3). Administration of AdMBP-AR reduced the tumor size significantly as early as day 11 following treatment, and prostate tumor growth did not increase over time (P < 0.0001 between MBP-AR and saline, P < 0.0001 between AdMBP-AR and Ad[β-gal]). In fact, all tumors disappeared as observed following AdMBP-AR administration. Administration of full-length MBP-1 also reduced tumor size. However, a slow growth was observed after 47 days of treatment and continued to grow until day 69 when all the mice were sacrificed (P < 0.001 between MBP-1 and saline, P < 0.001 between AdMBP-1 and Ad[β-gal]). Together, these results suggested that administration of AdMBP-AR or full-length MBP-1 significantly reduced prostate tumor growth and the MBP-AR possesses a stronger antitumor activity.

In summary, we have shown that the repressor domains of MBP-1 exert an antiproliferative effect on prostate cancer cell growth by inducing apoptosis. MBP-1-mediated apoptosis in prostate cancer cells involves PARP cleavage without activation of caspases. In a prostate tumor xenograft model, MBP-CR displayed a stronger antitumor activity as compared with MBP-AR. Furthermore, i.t. administration of MBP-CR was more pronounced against prostate tumor growth as compared with the full-length MBP-1. Earlier studies have shown that administration of recombinant adenovirus encoding the ligand-binding ectodomain of the vascular endothelial growth factor receptor 2 fused to an Fc domain reduced prostate tumor growth by 66% for orthotopic LNCaP tumors and by 42% for spontaneous tumors in TRAMP mice (13). Introduction of the posttranslationally phosphorylated mutant Bik into prostate tumors enhanced antitumor activity as compared with the wild-type (14). Treatment of human non-small cell lung carcinoma and bladder carcinoma cells by a recombinant adenovirus vector expressing the NH2-terminal truncated retinoblastoma protein (pRB94) completely suppressed the tumorigenicity in nude mice (15). Although adenovirus-mediated gene transfer of both full-length retinoblastoma and pRB94 induce human pancreatic tumor regression in a mouse xenograft, the pRB94 was evidently more potent than the full-length retinoblastoma (16). In conclusion, we have used an established animal model for testing the therapeutic potential of MBP-1 and its repressor domains. The COOH-terminal repressor domain of MBP-1 was proven to have a strong antitumor activity and could be useful in gene therapy against prostate cancer growth. Therefore, it may be possible to design a small molecule to mimic the structure of this peptide by constructing a fusion protein or using a synthetic peptide for specific targeting of prostate cancer cells.

Acknowledgments


Grant support: PHS grant CA52977 from the NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dana Oliver for statistical analysis.

References

Carboxyl-Terminal Repressor Domain of MBP-1 is Sufficient for Regression of Prostate Tumor Growth in Nude Mice

Asish K. Ghosh, Robert Steele and Ratna B. Ray


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/3/718

Cited articles
This article cites 15 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/3/718.full#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/3/718.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.